Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a five-year survival rate of approximately 5–10%. The immune checkpoint blockade represented by PD-1/PD-L1 inhibitors has been effective in a variety of solid tumors.
Agent/Drug | Combination Regimens | Targets | Phase | Number Enrolled | Trial ID | Primary Outcome(s) |
---|---|---|---|---|---|---|
Pembrolizumab | Cyclophosphamide + GVAX + SBR | PD-1 | II | 58 | NCT02648282 | DMFS |
Defactinib | PD-1 | I/II | 59 | NCT02758587 | AEs, DLTs, MTD | |
Cyclophosphamide + GVAX + IMC-CS4 | PD-1 | Early I | 12 | NCT03153410 | CD8 T cell density, AEs | |
Epacadostat + CRS-207 + CY + GVAX | PD-1 | II | 40 | NCT03006302 | DMFS | |
Olaparib | PD-1 | II | 20 | NCT05093231 | ORR | |
Cabozantinib | PD-1 | II | 21 | NCT05052723 | PFS | |
Defactinib | PD-1 | II | 36 | NCT03727880 | pCR rate | |
ENB003 | PD-1 | I/II | 130 | NCT04205227 | ORR, TRAEs | |
ONC-392 | PD-1 | I/II | 468 | NCT04140526 | DLT, MTD, TRAEs, RP2D | |
Tadalafil Ipilimumab CRS-207 |
PD-1 | II | 20 | NCT05014776 | ORR | |
PEGPH20 | PD-1 | II | 35 | NCT03634332 | PFS | |
Lenvatinib | PD-1 | II | 590 | NCT03797326 | ORR (initial), ORR (expansion), AEs, Discont due to AE | |
V941 | PD-1 | I | 100 | NCT03948763 | DLTs, AEs | |
CPI-006 + ciforadenant | PD-1 | I | 378 | NCT03454451 | Incidence of DLTs, TRAEs; MDL | |
INT230-6 + anti-CTLA-4 antibody | PD-1 | I/II | 110 | NCT03058289 | TRAEs | |
BCA101 | PD-1 | I | 292 | NCT04429542 | DLTs, safety, tolerability | |
Spartalizumab | Siltuximab | PD-1 | I/II | 42 | NCT04191421 | MTD |
Canakinumab injection + nab-paclitaxel + gemcitabine | PD-1 | I | 10 | NCT04581343 | RP2/3D | |
Dostarlimab | Niraparib | PD-1 | II | 20 | NCT04493060 | DCR |
Sintilimab | Gemcitabine + Albumin-paclitaxel | PD-1 | II | 20 | NCT05346146 | % R0 resection |
Surufatinib + AG | PD-1 | II | 32 | NCT05481476 | ORR | |
Toripalimab | Anlotinib + Nab-paclitaxel | PD-1 | II | 53 | NCT04718701 | PFS |
YH003 + Nab-paclitaxel + Gemcitabine | PD-1 | II | 129 | NCT05031494 | ORR | |
Camrelizumab | Nab paclitaxel + Gemcitabine Injection | PD-1 | II | 117 | NCT04498689 | ORR, PFS |
Chemotherapy + Ablation | PD-1 | Not Applicable | 34 | NCT04420130 | 6-month PFS rate | |
Surufatinib + nab-paclitaxel + S-1 gemcitabine |
PD-1 | II | 68 | NCT05218889 | DLTs, ORR, RP2D | |
Paclitaxel (Albumin Bound) + Gemcitabine + Placebo | PD-1 | III | 401 | NCT04674956 | PFS | |
Apatinib | PD-1 | II | 48 | NCT04415385 | ORR | |
Capecitabine | PD-1 | I | 20 | NCT04932187 | AEs | |
Nivolumab | Tadalafil + oral vancomycin | PD-1 | II | 22 | NCT03785210 | BOR |
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell) | PD-1 | I/II | 51 | NCT05162118 | DCR (phase 2), MTD, AEs, DLT (phase 1), RP2D (phase 1) | |
Cyclophosphamide + Ipilimumab + GVAX Pancreas Vaccine + CRS-207 | PD-1 | II | 63 | NCT03190265 | ORR | |
Ipilimumab + Stereotactic body radiation therapy + Low dose irradiation | PD-1 | I | 10 | NCT05088889 | ORR | |
Nivolumab | Anetumab Ravtansine + Gemcitabine Hydrochloride + Ipilimumab | PD-1 | I/II | 74 | NCT03816358 | MTD |
Irreversible Electroporation (IRE) + Toll-Like Receptor 9 | PD-1 | I | 18 | NCT04612530 | Safety | |
Irreversible electroporation (IRE) | PD-1 | II | 12 | NCT05435053 | Safety, tolerability | |
SX-682 | PD-1 | I | 20 | NCT04477343 | MTD | |
Cyclophosphamide + GVAX Pancreas Vaccine + Stereotactic Body Radiation (SBRT) | PD-1 | II | 30 | NCT03161379 | CD8 count in the TME | |
Cabiralizumab | PD-1 | I | 313 | NCT02526017 | ORR, RD, Safety | |
AK105 | Anlotinib | PD-1 | I/II | 29 | NCT04803851 | DCR |
Camrelizumab | Paclitaxel (Albumin Bound) + Gemcitabine | PD-1 | III | 401 | NCT04674956 | PFS |
Anti-PD-1 mAb | PD-1 | III | 830 | NCT03983057 | PFS | |
Anti-PD-1 antibody | Chemotherapy | PD-1 | III | 110 | NCT03977272 | OS |
Radiation | PD-1 | II | 21 | NCT03374293 | Local control | |
SBRT | PD-1 | I | 36 | NCT03716596 | OS | |
Radiotherapy + Gemcitabine + cisplatin + Apatinib | PD-1 | 150 | NCT04365049 | PFS | ||
Durvalumab | Gemcitabine | PD-L1 | II | 71 | NCT03572400 | DFS |
Tremelimumab + Gemcitabine + Minimally Invasive Surgical Microwave Ablation | PD-L1 | II | 20 | NCT04156087 | PFS | |
Olaparib + Radiation Therapy | PD-L1 | I | 18 | NCT05411094 | DLTs | |
Radiotherapy + Tremelimumab | PD-L1 | I | 30 | NCT02639026 | Number of AEs | |
Gemcitabine + Nab-paclitaxel + Oleclumab | PD-L1 | II | 30 | NCT04940286 | Incidence of AEs, RR | |
Romidepsin + Azacitidine + nab-Paclitaxel + Gemcitabine + Lenalidomide capsule | PD-L1 | I/II | 75 | NCT04257448 | RDE, safety and tolerability | |
Capecitabine + Bevacizumab + CV301 | PD-L1 | I/II | 8 | NCT03376659 | PFS(4 and 8.5 month) RP2D | |
Oleclumab+gemcitabine + nab-paclitaxel + oxaliplatin + leucovorin + 5-FU | PD-L1 | I/II | 212 | NCT03611556 | Incidence of AEs, clinically significant ECG abnormalities and laboratory values, ORR | |
Tazemetostat | PD-L1 | II | 173 | NCT04705818 | Assessment of antitumor activity | |
Galunisertib | PD-L1 | I | 37 | NCT02734160 | DLTs | |
Avelumab | Aldoxorubicin HCl + ALT-803 + ETBX-011 + GI-4000 etc. | PD-L1 | I/II | 173 | NCT03387098 | Incidence of AEs and SAEs, ORR |
ALT-803 + ETBX-011 + GI-4000 + haNK etc. | PD-L1 | I/II | 80 | NCT03329248 | Incidence of AEs and SAEs, ORR | |
Aldoxorubicin HCl + ALT-803 + ETBX-011 + ETBX-021 etc. | PD-L1 | I/II | 173 | NCT03586869 | Incidence of AEs and SAEs, ORR | |
Cyclophosphamide + Oxaliplatin + Capecitabine + 5-Fluorouracil etc. | PD-L1 | I/II | 3 | NCT03136406 | Incidence of AEs and SAEs, ORR | |
Atezolizumab | Cabozantinib | PD-L1 | II | 29 | NCT04820179 | ORR or stable disease |
KY1044 | PD-L1 | I/II | 412 | NCT03829501 | Safety, tolerability, DLTs, ORR, survival rate | |
FT500 + Nivolumab + Pembrolizuma + Cyclophosphamide etc. | PD-L1 | I | 37 | NCT03841110 | DLTs | |
RO7198457 + mFOLFIRINOX | PD-L1 | I | 29 | NCT04161755 | Toxicity | |
MEDI4736 | Tremelimumab | PD-L1 | II | 64 | NCT02527434 | OR |
SHR-1701 (PD-L1/TGF-β bsAb) | PD-L1 | I/II | 56 | NCT04624217 | ORR, RP2D | |
Pembrolizumab | Cabozantinib (RKTs Inhibitor) | PD-L2 | II | 21 | NCT05052723 | PFS |
PEGPH20 | PD-L2 | II | 35 | NCT03634332 | PFS | |
CD276 CAR-T cells | B7-H3 | I/II | 10 | NCT05143151 | ORR | |
MGD009 (B7-H3/CD3 bsAb) | B7-H3 | I | 67 | NCT02628535 | AEs | |
SGN-B7H4V (B7-H4 ADC) | B7-H4 | I | 375 | NCT05194072 | AEs, DLTs, laboratory abnormalities | |
HS-20089 (B7-H4 ADC) | B7-H4 | I | 177 | NCT05263479 | MTD | |
JNJ-61610588 (B7-H5 mab) | VISTA | I | 12 | NCT02671955 | Markers of monocyte activation, T-cell activation, immune infiltration; total blood cell counts; protein expression of VISTA; DLTs; AEs; SAEs |
This entry is adapted from the peer-reviewed paper 10.3390/ijms232315005